Table 5.

Multivariate analysis for progression free survival and overall survival for patients with non-small-cell lung cancer treated immune checkpoint inhibitor monotherapy

	HR (95% CI)	p
Independent factors for PFS
ECOG-PS (≥ 2 vs. 0/1)	1.43 (1.01–2.01)	0.043
EGFR mutation status (positive vs. negative/unknown)	3.60 (2.17–5.97)	< 0.001
Maximum diameter of target lesions (max BTS ≤ 50 mm vs. > 50 mm)	1.44 (1.03–2.02)	0.032
Independent factors for OS
ECOG-PS (≥ 2 vs. 0/1)	1.81 (1.23–1.43)	0.0027
Presence of bone metastasis (yes vs. no)	1.86 (1.24–2.78)	0.0025
EGFR mutation status (positive vs. negative/unknown)	3.12 (1.81–5.38)	< 0.001
Initially chosen ICI (pembrolizumab vs. atezolizumab)	0.51 (0.26–0.97)	0.041
GRIm score (high vs. low)	1.56 (1.02–2.38)	0.039
Maximum diameter of target lesions (max BTS ≤ 50 mm vs. > 50 mm)	1.51 (1.02–2.22)	0.038

PFS progression free survival, OS overall survival, NSCLC non-small-cell lung cancer, ICI Immune Checkpoint Inhibitor, HR hazard ratio, CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group-performance status, EGFR epidermal growth factor receptor, GRIm score Gustave Roussy Immune Score, BTS baseline tumor size